Bentley Pharmaceuticals Announces Research and Licensing Agreements for Intranasal Pain Management and Topical Hormone Replacement Therapy.Business Editors NORTH HAMPTON North Hampton is the name of several places in the United States:
License Will Follow Initial Success in Applying CPE-215(R) Technology to Topical Delivery of Testosterone Bentley Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol) BNT Boston Naming Test (psychology) BNT Bermuda National Trust BNT Bulgarian National TV BNT Broadband Network Termination BNT Binary File Transfer ), a U.S.-based drug delivery company with a commercial presence in Europe where it markets branded and generic products, announced today that it has entered into agreements with Auxilium A2, Inc. to license a new non-oral delivery formulation of a narcotic narcotic, any of a number of substances that have a depressant effect on the nervous system. The chief narcotic drugs are opium, its constituents morphine and codeine, and the morphine derivative heroin. See also drug addiction and drug abuse. for pain management and a new topical product for hormone replacement therapy Hormone Replacement Therapy Definition Hormone replacement therapy (HRT) is the use of synthetic or natural female hormones to make up for the decline or lack of natural hormones produced in a woman's body. , both in combination with CPE-215(R). These agreements follow the initial success of Bentley's license of a topical formulation of testosterone to Auxilium A2, which entered Phase III clinical trials in the first quarter of 2001. Each collaboration begins with a research agreement to characterize Bentley's formulations and, upon completion and acceptance by Auxilium A2, will become a worldwide license to Auxilium A2. Bentley will receive payments based upon the completion of specific milestones plus scaled royalties on net sales Net Sales The amount a seller receives from the buyer after costs associated with the sale are deducted. Notes: This amount is calculated by subtracting the following items from gross sales: merchandise returned for credit, allowances for damaged or missing goods, freight . Specific terms were not disclosed. Auxilium A2 is a Philadelphia-based pharmaceutical company with a focus on products which maintain normal function in an aging population and whose principals have a track record of thorough and rapid product development through regulatory approval. James R. Murphy, chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bentley, said, "Auxilium A2 has demonstrated its ability to develop products through clinical evaluation clinical evaluation Medtalk An evaluation of whether a Pt has symptoms of a disease, is responding to treatment, or is having adverse reactions to therapy in a highly efficient manner as evidenced by advancing our topical testosterone from concept into Phase III in less than one year. We are pleased to announce these additional agreements for products based upon our technologies for improving the absorption of a wide range of therapeutic agents. The pain product is our first intra-nasally administered product, and we are hopeful that clinical evaluation will progress in a successful fashion similar to the ongoing testosterone program. The objective of these new programs will be to develop a rapidly acting product for controlling acute and chronic pain." Bentley Pharmaceuticals, Inc. is a drug delivery company focused on improving the absorption of a wide range of drugs through its drug delivery technologies and manufactures and markets products in Europe for the treatment of cardiovascular, gastrointestinal, neurological and infectious diseases through its subsidiaries, Laboratorios Belmac S.A. and Laboratorios Davur S.L. Copies of the company's press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, the ability to find effective market distribution channels, development of new products, regulatory approval processes, the impact of competitive products or pricing, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion